A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Status:
Recruiting
Trial end date:
2023-08-23
Target enrollment:
Participant gender:
Summary
Assessment of PF-06700841 in participants with moderate to severe active, generalized
Systemic Lupus Erythematosus (SLE) that have inadequate response to standard of care.